INTRODUCTION
============

Clathrin is a major coat protein involved in vesicle formation during receptor-mediated endocytosis and sorting in the *trans*-Golgi network (TGN)/endosomal system ( [@B76]). Clathrin is found as a triskelion containing three extended heavy chains (CHCs) trimerized at their C-termini and three light chains (CLCs). These assemble into a characteristic polyhedral coat on the cytosolic face of the membrane to facilitate clathrin-coated vesicle (CCV) formation. CHC interacts with adaptor proteins, which are involved in recruitment of clathrin to the membrane, as well as the binding to and sorting of cargo. Although the role of CHC in CCV formation is well established, the roles of CLC are not completely understood.

Previous work showed that CLCs bind along the vertex-proximal region of the CHC leg and are found on the outer surface of the clathrin lattice, where they are positioned to interact with other cytosolic and regulatory factors ( [@B22]). They are important for stabilization of the mammalian triskelion hub fragments in vitro ( [@B88], [@B87]) and are essential for CHC trimerization in yeast ( [@B12]; [@B35]). Biochemical studies also show that CLC inhibits spontaneous triskelion self-assembly ( [@B77]; [@B49]), and this activity depends on the conserved N-terminal acidic region of CLC ( [@B86]). Recent work suggested that interaction of CLC or the CLC amino terminus with CHC might prevent the bending of the CHC knee that is required for lattice assembly ( [@B81]). However, depletion of CLC or overexpression of CLC lacking the N-terminal regulatory domain in animal cells has little effect on endocytosis, although some effect on TGN/endosomal sorting has been observed ( [@B34]; [@B11]; [@B59]; [@B80]).

The CLC N-terminal acidic region also interacts with the central coil-coiled dimerization domain of the Hip1/Hip1R/Sla2 family of proteins ( [@B11]; [@B45]; [@B56]). Some evidence suggests that Hip1/R binding to CLC promotes clathrin assembly by releasing the CLC N-terminal negative regulation on CHC ( [@B11]; [@B45]). Because Hip1-related proteins contain both an AP180 N-terminal homology domain (ANTH) that binds membrane-associated phosphatidyl inositides and a talin/Hip1/R/Sla2 actin-tethering C-terminal homology domain (THATCH) that binds F-actin, they may provide a critical link between the membrane and the actin cytoskeleton or regulate actin assembly during clathrin-mediated transport ( [@B52]; [@B85]; [@B44]; [@B36]; [@B64]; [@B70]; [@B9]; [@B80]). Depletion of Hip1 family proteins from cells leads to aberrant actin assemblies at clathrin-coated membranes in both yeast and animal cells ( [@B39]; [@B19]; [@B58]; [@B42]; [@B59]), and similarly treatments that affect the ability of CLC to interact with Hip1R in animal cells perturb actin structures at clathrin-coated membranes ( [@B11]; [@B59]; [@B80]; [@B62]). Still, the role of CLC regulation of Hip1 family proteins remains unclear.

Yeast provides elegant ways to address these questions by combining live-cell imaging with powerful molecular genetic tools. This model system has established a spatiotemporal map from recruitment to disassembly and is now elucidating details about the molecular functions of a large number of endocytic factors. Clathrin-mediated endocytosis in yeast takes place at cortical patches and involves many factors that have animal cell counterparts ( [@B17]; [@B61]; [@B25]). Generally the process has an immobile stage for establishing the endocytic site and a rapid, mobile phase when invagination and vesicle formation occur. During the immobile phase (1--2 min) several endocytic coat factors and adaptors collect at a cortical patch, including the F-BAR domain protein Syp1 (FCHO1/FCHO2 homologue), Ede1 (an Eps15 homology \[EH\] domain protein), and clathrin ( [@B58]; [@B7]; [@B60]; [@B69]). Later in the immobile phase Sla2 (Hip1/Hip1R) appears, followed by Sla1 (an SH3 domain--containing protein), the two EH domain factors Pan1 and End3, and the WASp homologue, Las17 ( [@B39], [@B40]; [@B57]). Many actin-binding or -remodeling proteins, such as Abp1, capping protein, and Arp2/3 complex, appear or are activated during the mobile phase, which lasts only 10--15 s ( [@B39], [@B40]). At the onset of the mobile phase, the WIP homologue, verprolin (Vrp1), localizes to the cortical site, where it recruits and activates the type-I myosins (Myo3/5), which are potent Arp2/3 activators believed to produce a final burst of actin needed to drive invagination ( [@B39], [@B40]; [@B38]; [@B71]; [@B24]). When the patch has invaginated ∼200--300 nm, the vesicle pinches off, facilitated by the N-BAR domain amphiphysin homologues Rvs161 and Rvs167, uncoating occurs, and the vesicle associated with actin moves deeper into the cell ( [@B39], [@B40]).

Here we explore how the CLC N-terminus (CLC-NT) regulates the yeast Hip1R homologue, Sla2. Sla2 arrives at endocytic sites well after clathrin, so it is not required for assembly of clathrin ( [@B56]; [@B57]). As in mammalian cells, deletion of *SLA2* leads to accumulation of early coat factors at the cortex and unproductive actin comet tails emanating from these sites ( [@B39]; [@B58]). Our previous work discovered that *CLC1,* which encodes CLC, is a high-copy suppressor of clathrin HC--deficient (*chc1Δ*) yeast, indicating that CLC possesses regulatory functions during endocytosis ( [@B35]). Furthermore, we isolated Sla2 as a CLC-interacting protein ( [@B32]); as in animal cells, the yeast CLC-NT interacts with the coiled-coiled domain of Sla2 ( [@B56]; [@B57]). Of interest, overexpression of the N-terminal Sla2-binding region of CLC suppresses the endocytic phenotypes of clathrin-null mutants, including progression of stalled Sla2-containing endocytic patches ( [@B56]). However, deletion of the CLC-NT alone has minimal effect on its own, likely due to redundancy of the endocytic machinery.

To further investigate the regulatory role of CLC during endocytic progression we took advantage of the genome-wide synthetic genetic array (SGA) approach ( [@B72]), using a *clc1* mutant encoding CLC lacking the Sla2-binding region (*clc1-Δ19-76*) as the query strain. To our surprise, the *clc1-Δ19-76* allele alleviated growth defects of null mutants for three late endocytic factors: verprolin (Vrp1) and the amphiphysins (Rvs161 and Rvs167). Our analysis of this suppression by live-cell imaging, combined with biochemical evidence, suggests that CLC negatively regulates Sla2 binding to the actin cytoskeleton to restrict the number and/or location of Sla2\'s actin attachments to promote internalization.

RESULTS
=======

Synthetic genetic array analysis with *clc1-Δ19-76*
---------------------------------------------------

We present the first SGA screen performed on a clathrin mutant. Genetic analysis of clathrin mutants previously were limited to small-scale screens ( [@B4], [@B5]), and large-scale SGA analysis was not done because clathrin-null yeast (*clc1Δ* or *chc1Δ*) exhibit massive polyploidy ( [@B47]; [@B35]), which renders them unreliable participants in these screens. To explore the mechanism of CLC regulation of endocytosis, we generated a strain (SL5677) for SGA analysis carrying an integrated mutation, *clc1-Δ19-76,* encoding CLC lacking the Sla2-binding residues ( [Figure 1A](#F1){ref-type="fig"}). CLC expression from *clc1-Δ19-76* was essentially the same as from wild-type *CLC1*; however, clathrin HC levels appeared to be slightly decreased in these cells ( [Figure 1, B and C](#F1){ref-type="fig"}). Except for a slight cold sensitivity (unpublished data), *clc1-Δ19-76* yeast were similar to wild-type yeast in all tests performed (see later discussion).

![Synthetic genetic array analysis with the *clc1-Δ19-76* allele. (A) Schematics of Clc1 and Clc1-Δ19-76*,* highlighting regions that bind Sla2 (blue), CHC (gray), or calmodulin (yellow) and the region comprising an EF hand motif (green). (B) Immunoblot of protein extracts from wild type (SL1462), *clc1-Δ19-76* (SL5677), and *clc1Δ* (SL1620) probed with anti-Clc1 and anti-Pgk1 (loading control). (C) Same as B, but probed with anti-Chc1 monoclonal antibodies. (D--G) Edges represent published physical protein--protein interactions; nodes are white if they were not in the screen and gray if no interaction was identified. If double mutants produced a synthetic growth defect relationship, they are labeled in red, and nodes demonstrating synthetic rescue with *clc1-Δ19-76* are labeled in green. (D) *clc1-Δ19-76* demonstrated a relationship with three AP-1--complex subunits (p ≤ 0.01). (E) Four of the five core retromer complex proteins were identified (p ≤ 0.01). (F) Three of the five components of the GET complex were identified (p ≤ 0.01). (G) Endocytic network showing hits from SGA analysis with *clc1-Δ19-76.*](3699fig1){#F1}

For SGA analysis *clc1-Δ19-76* was first systematically crossed to a collection of 177 temperature-sensitive (*ts*) alleles enriched for genes encoding proteins involved in membrane trafficking, endocytosis, and actin function (listed in Supplemental Table S1B). This screen identified 11 genes whose mutations caused synthetic growth defects in the presence of the *clc1* mutation, including the endocytic coat factor Pan1 and the Arp2/3 complex subunit Arp3 ( [Figure 1G](#F1){ref-type="fig"}), although the latter showed major differences, depending on the *arp3* allele, and might be complicated by additional functions of the Arp2/3 complex, for example, mitochondrial movement ( [@B8]). We confirmed the *pan1* genetic interaction with an additional allele, *pan1-20,* which was in fact synthetic lethal with *clc1-Δ19-76* (Supplemental Figure S1A). A larger-scale SGA screen involved crossing the *clc1-Δ19-76* mutant to 3885 strains from the viable deletion collection. This screen identified 336 aggravating mutations (synthetic growth phenotypes; Supplemental Table S3B) and 58 mutants whose growth phenotypes were alleviated by *clc1-Δ19-76* (synthetic rescue phenotypes; [Table 1](#T1){ref-type="table"}A and Supplemental Table S3A).

###### 

Selected genes identified by SGA screens.

  Gene                                                                         Description (homologue)
  ---------------------------------------------------------------------------- ------------------------------------------------------------------------
  **A. Null mutations showing synthetic rescue with *clc1-Δ19-76*^a^**         
  VRP1                                                                         WASp-interacting protein 1, regulates myosin I (WIP)
  VPH1                                                                         V-type proton ATPase 116-kDa subunit A
  YMR166C                                                                      Mitochondrial ATP-Mg/P~i~ carrier
  ELM1                                                                         Ser/Thr protein kinase, regulates morphogenesis and cytokinesis
  ROD1                                                                         Art4, α-arrestin
  CBF1                                                                         Centromere-binding factor
  FIS1                                                                         Mitochondrial fission protein (Fis1)
  EST1                                                                         Telomere elongation (hEST1A, hEST1B)
  RPL14A                                                                       Ribosomal protein L14 (RPL14)
  RVS167                                                                       BIN1/amphyphisin/endophilin
  SIN3                                                                         Histone deacetylase complex (SIN3A)
  LSM6                                                                         Like SM-protein involved in mRNA decay, U6 snRNP component
  CEX1                                                                         tRNA export from nucleus
  SHE4                                                                         Binds unconventional myosins
  VAC14                                                                        Regulation of phosphatidylinositol 3,5-bisphosphate synthesis (hVAC14)
  ARL1                                                                         ADP-ribosylation factor--like; TGN--endosomal transport (ARL)
  CSE2                                                                         RNA polymerase II transcription mediator complex
  GAP1                                                                         General amino acid permease
  EMI5                                                                         Succinate dehydrogenase subunit
  BRR1                                                                         Component of spliceosomal snRNPs
  ECM8                                                                         Unknown
  FMP23                                                                        Unknown
  PMA2                                                                         Plasma membrane H^+^ ATPase
  MAP2                                                                         Methionine aminopeptidase (METAP2)
  HOM6                                                                         Homoserine dehydrogenase
  CPR7                                                                         Peptidyl-prolyl *cis*--*trans* isomerase
  PEX27                                                                        Peripheral peroxisomal membrane protein
  UBP6                                                                         Ubiquitin-specific protease of proteosome (USP14)
  BER1                                                                         Unknown
  SNU66                                                                        Component of the U4/U6.U5 snRNP complex
  PAT1                                                                         Deadenylation-dependent mRNA-decapping factor
  RVS161                                                                       BIN1/amphyphisin/endophilin
  SYS1                                                                         Golgi membrane protein
                                                                               
  **B. *ts* mutants showing synthetic growth defects with *clc1-Δ19-76*^b^**   
  ALG2                                                                         Mannosyltransferase (ALG2)
  ARP3                                                                         Component of the Arp2/3 complex (ACTR3B)
  COP1                                                                         α subunit of COPI coatomer complex (COPA)
  LST8                                                                         Torc1/2 component
  MCD4                                                                         Involved in GPI anchor synthesis (PIGN)
  PAN1                                                                         EH domain containing endocytic factor
  PIK1                                                                         Phosphatidylinositol 4-kinase
  SEC2                                                                         Post-Golgi GEF for Sec4
  SEC21                                                                        γ subunit of coatomer (COPG2)
  YIF1                                                                         Fusion of ER-derived COPII vesicles (YIF1A)
  YIP1                                                                         Fusion of ER-derived COPII vesicles (YIPF5)

snRNP, small nuclear ribonucleoprotein.

^a^Genes whose null mutation caused synthetic rescue phenotypes in combination with *clc1-Δ19-76* with an ε \> 0.180 and p \< 0.015. Results are ranked by ε score. Verprolin (*VRP1*) and both amphiphysins (*RVS167* and *RVS161*) are highlighted in red.

^b^Genes with an adjusted calibrated p between 0.1 and 1, ranked by this value.

Gene ontology categories were used to sort the data set by biochemical processes (Supplemental Table S2). Fifteen percent of genes identified by the deletion screen were associated with the Gene Ontology term "vesicle transport," in vast excess of the expected 5% found in the genome (p ≤ 7 × 10^−11^). Several protein complexes showed statistically significant representation in our data (i.e., greater than expected for the size of the data set). Included was the clathrin-associated TGN/endosomal AP-1 adaptor complex (p \< 0.01; [Figure 1D](#F1){ref-type="fig"}). These negative genetic interactions are consistent with previous work combining clathrin and AP-1 adaptor mutations ( [@B68]; [@B89]). Negative genetic interactions were also observed with a number of other factors involved in retrograde transport from the endosome to the TGN (Supplemental Table S2), including most components of the retromer complex ( [Figure 1E](#F1){ref-type="fig"}; p \< 0.01). We hypothesize that this exacerbated growth phenotype was caused by impairment of two parallel retrograde pathways from the endosome, one involving clathrin and another involving retromer. In addition, we identified several subunits of the GET complex, which is required for insertion of tail-anchored proteins into the endoplasmic reticulum (ER) ( [@B65]) ( [Figure 1F](#F1){ref-type="fig"}; p \< 0.01). GET complex--requiring soluble *N*-ethylmaleimide--sensitive factor attachment protein receptors, such as SNC2 and VAM3, were also identified, suggesting that GET complex interactions may just phenocopy the loss of these downstream targets.

In accordance with the previously described clathrin synthetic lethality screen using a *ts chc1* allele, *chc1-521* ( [@B4], [@B5]), we identified four mutants (*ric1,* *gga1,* *vps21,* and *inp53*) with synthetic growth defects in combination with *clc1-Δ19-76.* We suspect that some of these negative genetic interactions with the *clc1* mutant may be related to the reduced levels of Chc1; however, we cannot rule out that the CLC-NT has some TGN/endosomal--specific function. Genetic interactions involving mutations affecting other stages of the secretory/endosomal transport pathways and a number of membrane transporters were identified (Supplemental Table S2). Others were observed with genes important for cell wall biosynthesis, glycosylation, lipid/sphingolipid and phosphatidyl inositide synthesis, and components affecting ubiquitin modification. The last-named observation is consistent with previous studies showing that clathrin-deficient yeast accumulate ubiquitinated conjugates and deplete cellular ubiquitin stores ( [@B55]).

In addition to *pan1* and *arp3* found in the *ts* screen, a null allele of *EDE1,* which encodes an EH-domain early endocytic adaptor, caused synthetic growth defects in combination with *clc1-Δ19-76* ( [Figure 1G](#F1){ref-type="fig"}). Most interesting was that *clc1-Δ19-76* suppressed the growth defects of null mutations for three late-stage endocytic factors: Vrp1 (verprolin, the type I myosin activator related to WIP) and Rvs161 and Rvs167 (amphiphysins involved in vesicle scission; [Figure 1G](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). These unusual positive genetic interactions seemed more likely to yield mechanistic insight into the role of the CLC-NT. Thus we focused primarily on *vrp1* and *rvs167* since their ε scores were high, but *rvs161* gave similar, although more subtle effects, as shown for *rvs167.*

The *clc1-Δ19-76* allele suppresses growth and endocytic defects of *vrp1Δ* and *rvs167Δ*
-----------------------------------------------------------------------------------------

To ensure the validity of these genetic interactions, the *clc1-Δ19-76* mutation was recapitulated in our SL1462 lab strain and crossed to either *vrp1Δ* or *rvs167Δ.* Whereas *clc1-Δ19-76* yeast grew well at 30 or 37°C, *vrp1* ( [Figure 2A](#F2){ref-type="fig"}) and *rvs167Δ* ( [Figure 2B](#F2){ref-type="fig"}) cells were *ts* at 37°C. Consistent with the SGA screen, *clc1-Δ19-76* suppressed the *ts* growth of *vrp1Δ* ( [Figure 2A](#F2){ref-type="fig"}) and *rvs167Δ* ( [Figure 2B](#F2){ref-type="fig"}) at 37°C. Actin polarity defects are often associated with endocytic mutations. *clc1-Δ19-76* cells were polarized like wild type, and the *clc1* allele substantially suppressed the polarity defects caused by *vrp1Δ* or *rvs167Δ* as well ( [Figure 2, C and D](#F2){ref-type="fig"}).

![*clc1-Δ19-76* suppresses the growth, actin polarity, and fluid-phase endocytosis defects of verprolin and amphiphysin null mutants. (A) Growth with *vrp1Δ*: wild type (SL1462), *clc1-Δ19-76* (SL6044), *vrp1Δ* (SL4136), and *vrp1Δ clc1-Δ19-76* (SL6049) were fivefold serially diluted, plated on YEPD, and grown at 30 or 37°C for 60 h. (B) Growth with *rvs167Δ*: wild type (SL1462), *clc1-Δ19-76* (SL6044), *rvs167Δ* (RH2951), and *rvs167Δ clc1-Δ19-76* (SL6052) were plated and grown as in A. (C) Actin polarization: strains shown in A and B were grown at 25°C, fixed, and stained with Alexa Fluor 568--phalloidin. Each image is a max-Z projection of 12 (0.2 μm) optical sections after nearest-neighbor deconvolution (bar, 5 μm). (D) Quantification of actin polarization reported as percentage of small and medium budded cells with \>50% of phalloidin stain in the bud (n = 75). (E) Example micrographs of strains indicated in A and B after Lucifer yellow (LY) uptake for 1 h at 25°C (bar, 5 μm). (F) Quantification of LY uptake reported as percentage of cells with vacuolar LY (n = 90).](3699fig2){#F2}

Lucifer yellow (LY) uptake assays were used to test bulk fluid-phase endocytosis ( [Figure 2, E and F](#F2){ref-type="fig"}). LY uptake in the *clc1-Δ19-76* mutant was similar to wild type. As expected, both *vrp1Δ* and *rvs167Δ* yeast had minimal uptake, with only 5--8% of cells with labeled vacuoles. However, when combined with the *clc1-Δ19-76* allele there was significant restoration of LY internalization compared with either null allele alone ( [Figure 2, E and F](#F2){ref-type="fig"}). Similarly the LY uptake defect in *rvs161Δ* was suppressed by *clc1-Δ19-76* (Supplemental Figure S1B). Because we saw no defect in growth at elevated temperature, polarity, or LY uptake in the *clc1-Δ19-76* mutant alone, we conclude that this mutation suppresses the defects caused by the verprolin or amphiphysin gene deletions.

*clc1-Δ19-76* rescues *vrp1Δ* defects in endocytic dynamics and inward vesicle movement
---------------------------------------------------------------------------------------

Previous reports showed that verprolin arrives at the endocytic patch just prior to the actin phase, where it plays a role in the recruitment and activation of the potent Arp2/3--activating type I myosins (Myo3 and Myo5), which are important for actin-dependent membrane invagination ( [@B1]; [@B20]; [@B26]; [@B66]; [@B71]). Thus, inward movement of endocytic patches is defective in *vrp1Δ* yeast because of reduced Myo3/5 at the patch and impaired activation of residual myosin present ( [@B71]). To visualize whether *clc1-Δ19-76* suppressed the defects of *vrp1Δ,* we combined these mutations with early endocytic markers (either Sla2--green fluorescent protein \[GFP\] or Sla1-GFP) and a mobile phase/actin marker (Abp1--red fluorescent protein \[RFP\]), and collected time-lapse movies of their dynamics in live cells. Unlike growth defects, which were best observed at elevated temperatures, the endocytic defects of *vrp1Δ* (and *rvsΔ*; see later discussion) were highly penetrant, so movies were taken at 25°C.

The *clc1-Δ19-76* mutation alone caused no significant change in the lifetime of any endocytic marker we tested, and invagination was normal ( [Figure 3, A--C](#F3){ref-type="fig"}, and unpublished data). In contrast, *vrp1Δ* yeast demonstrated dramatic lifetime elongation of both Sla1-GFP and Sla2-GFP ( [Figure 3, A--C](#F3){ref-type="fig"}). Sla1-GFP lifetimes were prolonged from 31 ± 6 s in wild type to 69 ± 17 s in *vrp1Δ* (p \< 0.0001; [Figure 3, A and C](#F3){ref-type="fig"}). Sla2-GFP was more severely affected, with lifetimes extended from 49 ± 15 s in wild type to 165 ± 57 s in the verprolin mutant (p ≤ 0.0001; [Figure 3, B and C](#F3){ref-type="fig"}). Combining *clc1-Δ19-76* with *vrp1Δ* significantly reduced the lifetimes of both Sla1-GFP (to 56 ± 14 s; p ≤ 0.001) and Sla2-GFP (to 73 ± 25 s; p ≤ 0.0001; [Figure 3, A--C](#F3){ref-type="fig"}). Of note, there was also an elongation of the actin stage of endocytosis in *vrp1Δ,* as marked by Abp1-RFP, but this was not suppressed by the *clc1-Δ19-76* mutation.

![Defects in endocytic dynamics of *vrp1Δ* are suppressed when combined with *clc1-Δ19-76.* (A) Representative kymographs of Sla1-GFP/Abp1-RFP patches in wild type (SL5311), *clc1-Δ19-76* (SL6068), *vrp1Δ* (SL6065), and *vrp1Δ clc1-Δ19-76* (SL6062). (B) Representative kymographs of Sla2-GFP/Abp1-RFP patches in wild type (SL5927), *clc1-Δ19-76* (SL6084), *vrp1Δ* (SL6081), *vrp1Δ clc1-Δ19-76* (SL6077). (C) Fluorescence lifetimes of Sla2-GFP, Sla1-GFP, and Abp1-RFP in strains shown in A and B. Data are reported as average ± SD (n ≥ 50). †p ≤ 0.0001 vs. wild type; ‡*p* ≤ 0.0001 vs. *vrp1Δ*; \#p ≤ 0.001 vs. *vrp1Δ.* (D) Tangential kymographs illustrating inward movement of Sla2-GFP/Abp1-RFP endocytic patches in wild type, *vrp1Δ,* and *vrp1Δ clc1-Δ19-76.* (E) Percentage of Sla2-GFP/Abp1-RFP patches that demonstrate "normal" inward movement (n *= 90*). (F) Example plots of Sla2-GFP trajectories comparing inward movement from wild type, *vrp1Δ,* and *vrp1Δ clc1-Δ19-76.* Each point represents a 2-s frame, with the length of the lines between frames indicating distance moved. Initial coordinates are highlighted in green, and the final time points are in red.](3699fig3){#F3}

The invagination defect caused by *vrp1* was also suppressed by *clc1-Δ19-76.* In *vrp1Δ* 80% of Sla2 patches accumulated some degree of Abp1-RFP ( [Figure 3, D--F](#F3){ref-type="fig"}), but only 20% of these showed any movement inward from the cortex. This percentage increased to 47% in *vrp1Δ clc1-Δ19-76* ( [Figure 3, D--E](#F3){ref-type="fig"}). This was also seen in single-particle tracking of movement of Sla2-GFP, which normally invaginates 200--300 nm with the forming vesicle and disassembles shortly after vesicle scission. The depth of Sla2-GFP inward movement was impeded in *vrp1Δ* (65 ± 13 nm vs. 250 ± 20 nm in wild type, n = 10), but this was restored to near wild-type distances (190 ± 43 nm, n = 10) in *vrp1Δ clc1-Δ19-76* ( [Figure 3F](#F3){ref-type="fig"}).

*clc1-Δ19-76* rescues *rvs167Δ* defects in endocytic dynamics
-------------------------------------------------------------

Rvs161 and Rvs167 form a heterodimer through their N-terminal N-BAR domain and are recruited late to endocytic sites ( [@B40]; [@B23]). These proteins require one another for stable expression, and deletion of either of these proteins causes endocytic defects ( [@B53]; [@B50]; [@B23]). Notable in amphiphysin-null mutants is a retraction behavior, in which endocytic patches begin to internalize but then return to the cell cortex and dissipate, consistent with a role in vesicle scission ( [@B40]; [@B90]).

By time-lapse imaging we found that Sla2-GFP lifetimes were lengthened by twofold in *rvs167Δ,* but the *clc1-Δ19-76* allele restored Sla2 lifetimes to near wild type (99 ± 33 vs. 54 ± 21 s, p ≤ 0.0001, *rvs167Δ* vs. *rvs167Δ clc1-Δ19-76,* respectively) ( [Figure 4, B and C](#F4){ref-type="fig"}). The *clc1-Δ19-76* mutation also significantly reduced the lifetimes of Sla1-GFP (51 ± 14 vs. 44 ± 13 s, p ≤ 0.03, *rvs167Δ* vs. *rvs167Δ clc1-Δ19-76,* respectively; [Figure 4, A](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}). Similar although more subtle results were obtained in *rvs161Δ* yeast (Supplemental Figure S1C). In addition, combining the *clc1-Δ19-76* allele with either *rvs167Δ* or *rvs161Δ* increased the number of internalizing patches and reduced the retraction of endocytic markers back to the cortex as compared with either *rvs* mutant alone ( [Figure 4D](#F4){ref-type="fig"} and Supplemental Figure S1D).

![Defects in endocytic dynamics of *rvs167Δ* are suppressed when combined with *clc1-Δ19-76.* (A) Representative kymographs of Sla1-GFP/Abp1-RFP patches in wild type (SL5311), *clc1-Δ19-76* (SL6068), *rvs167Δ* (SL6108), and *rvs167Δ clc1-Δ19-76* (SL6191). (B) Representative kymographs of Sla2-GFP/Abp1-RFP patches in wild type (SL5927), *clc1-Δ19-76* (SL6084), *rvs167Δ* (SL6196), and *rvs167Δ clc1-Δ19-76* (SL6197). (C) Fluorescence lifetimes of Sla2-GFP, Sla1-GFP, and Abp1-RFP in strains shown in A and B. Data are reported as average ± SD (n ≥ 50). †p ≤ 0.0001 vs. wild type; ‡p ≤ 0.0001 vs. *rvs167Δ*; \#p ≤ 0.03 vs. *rvs167Δ.* (D) Percentage of patches that show "normal" inward movement following Abp1 accumulation (n = 90). Similar results were obtained for *rvs161Δ* (see Supplemental Figure S1).](3699fig4){#F4}

Neither *vrp1Δ* nor *rvs167Δ* is suppressed by *clc1Δ*
------------------------------------------------------

To test whether the suppression by *clc1-Δ19-76* was unique to this *clc1* allele and not due to general loss of CLC function or the slightly reduced levels of clathrin HC, we tested the ability of the null *clc1Δ* to suppress *vrp1Δ* or *rvs167Δ* growth and endocytosis. In either case neither temperature sensitivity nor endocytic dynamics was rescued ( [Figure 5](#F5){ref-type="fig"}). The endocytic profiles seen in *vrp1Δ clc1Δ* yeast were more characteristic of a clathrin-null than a verprolin-null mutant ( [@B57]) since nearly 77% of Sla2-GFP patches persisted longer than 360 s ( [Figure 5B](#F5){ref-type="fig"}). Of interest, the characteristic actin comet tails caused by *clc1Δ* were missing in *vrp1Δ clc1Δ* cells, probably due to impaired recruitment of the type I myosins in *vrp1* and, as a consequence, reduced actin assembly. *rvs167Δ clc1Δ* cells also had severe endocytic defects ( [Figure 5D](#F5){ref-type="fig"}). Again, 77% of all Sla2-GFP patches were arrested, and in these cells dramatic actin comet tails were evident in 23% of patches.

![*vrp1Δ* and *rvs167Δ* are not suppressed by a clathrin LC null (*clc1Δ*). (A) Wild type (SL1462), *clc1Δ* (SL1620), *vrp1Δ* (SL4136), and *vrp1Δ clc1Δ* (SL6290) were fivefold serially diluted, plated on YEPD, and grown at 30 or 37°C for 60 h. (B) Kymographs of Sla2-GFP and Abp1-RFP in *vrp1Δ clc1Δ* (SL6291) illustrating the types of dynamic behaviors observed and percentages of each (n = 60). (C) Wild type (SL1462), *clc1Δ* (SL1620), *rvs167Δ* (RH2951), and *rvs167Δ clc1Δ* (SL6292) were plated and grown as indicated in A. (D) Kymographs of Sla2-GFP and Abp1-RFP in *rvs167Δ clc1Δ* (SL6293) illustrating the types of dynamic behaviors and percentages of each (n = 60).](3699fig5){#F5}

*clc1-Δ19-76* suppression of *vrp1Δ* and *rvs167Δ* requires actin binding by Sla2
---------------------------------------------------------------------------------

As shown earlier, deletion of the N-terminus of CLC suppressed the loss of Vrp1 and Rvs proteins, three components of the actin phase of internalization. Because CLC-N terminus binds directly to the Sla2 coiled-coil region and Sla2 binds directly to F-actin through its THATCH domain, we considered the possibility that the *clc1-Δ19-76* mutant effects were mediated through altered ability to regulate Sla2 actin binding. Therefore we examined the effect of CLC on Sla2 in vitro using F-actin cosedimentation assays. Purified glutathione *S*-transferase (GST) fusions of Sla2 ( [Figure 6A](#F6){ref-type="fig"}) were incubated with preassembled F-actin and pelleted at high speed ( [Figure 6, B](#F6){ref-type="fig"} and [C](#F6){ref-type="fig"}, and Supplemental Figure S2). All Sla2 fragments with the THATCH domain bound to F-actin. When the clathrin LC--binding site was present (GST-Sla2-292-968), preincubation with a 5 M excess of histidine (His) 6-tagged-LC (6xHis-Clc1) reduced cosedimentation dramatically ( [Figure 6B](#F6){ref-type="fig"} and Supplemental Figure S2D). Similar results were found for full-length GST-Sla2 (Supplemental Figure S2, A and D); however, in our hands GST-Sla2 was considerably less stable and less soluble than fragments lacking the ANTH domain (unpublished data). In contrast, the THATCH domain alone (GST-Sla2-717-968), lacking the clathrin LC--binding region, bound actin even in the presence of 6xHis-Clc1 ( [Figure 6C](#F6){ref-type="fig"} and Supplemental Figure S2D). GST-Crn1 (coronin) was tested as a positive control for F-actin binding and was found to bind actin in the presence or absence of Clc1 (Supplemental Figure S2D and unpublished data). Neither bovine serum albumin contained in the actin-binding buffer (Supplemental Figure S2C) nor GST (unpublished data) bound nonspecifically to F-actin. Overall these results indicate that CLC inhibits the ability of Sla2 to bind to actin.

![Clathrin LC inhibits Sla2 binding to F-actin. (A) GST-Sla2 fusions used in actin binding assays. Schematic highlights sequences corresponding to the N-terminal ANTH domain (black), coiled-coil domain (light gray), and THATCH domain (dark gray). (B) Actin sedimentation assays performed using 3 μM GST-Sla2-292-968, with or without 10 μM F-actin and with or without 15 μM 6xHis-Clc1. (C) Actin sedimentation assays performed as in B using 3 μM GST-Sla2-717-968.D. Sla2 actin-binding THATCH domain is necessary for *clc1-Δ19-76* suppression: strains were fivefold serially diluted, plated on YEPD, and grown at 30 and 37°C. Strains are *vrp1Δ clc1-Δ19-76* (SL6230), *vrp1Δ clc1-Δ19-76 sla2-Δthatch* (SL6231), *rvs167Δ clc1-Δ19-76* (SL6238), and *rvs167Δ clc1-Δ19-76 sla2-Δthatch* (SL6239).](3699fig6){#F6}

To determine whether *clc1-Δ19-76* suppression of *vrp1Δ* or *rvs167Δ* in vivo was mediated through Sla2, we tested whether the Sla2 C-terminal THATCH domain was required for this effect. A hemagglutinin (HA) tag was inserted at residue 717 of Sla2, causing a C-terminal truncation. As a control, an HA tag was inserted after the full-length Sla2 coding sequence. Deletion of the THATCH region caused no phenotype (unpublished data), as shown previously ( [@B79]; [@B85]). However, although *vrp1Δ clc1-Δ19-76* or *rvs167Δ clc1-Δ19-76* cells could grow at 37°C, triple-mutant cells also containing the *sla2-Δthatch* allele were *ts* for growth ( [Figure 6D](#F6){ref-type="fig"}). Collectively these data indicate that the suppression by *clc1Δ19-76* depends on the interaction of Sla2 with F-actin through the Sla2 THATCH domain.

*clc1-Δ19-76* suppresses mutations in major actin nucleation--promoting factors
-------------------------------------------------------------------------------

At the endocytic patch F-actin is densely branched, requiring the Arp2/3 complex for assembly ( [@B28]). The Arp2/3 complex has little activity on its own since it requires an actin nucleation--promoting factor (NPF) to seed actin assembly ( [@B29]). In yeast, five endocytic NPFs have been identified: Pan1, Las17, Myo3, Myo5, and Abp1 ( [@B82]; [@B20]; [@B43]; [@B16]; [@B29]), although Pan1 and Abp1 are considered weak NPFs compared with the strong activities of Las17 or the type I myosins ( [@B71]). The WASp homologue, Las17, aids in recruitment of Vrp1, which in turn recruits and activates the redundant type I myosins Myo3 and Myo5 ( [@B1]; [@B20]; [@B26]; [@B66]; [@B71]; [@B83]). Because verprolin binds these three potent NPFs, we tested whether *clc1-Δ19-76* would suppress null mutations in these genes.

The *clc1-Δ19-76* mutation was crossed to a *myo3Δ myo5Δ* strain, and resultant segregants were tested for growth. *myo3Δ myo*5*Δ* mutants showed extremely impaired growth at both 30 and 37°C, but combining the double null with *clc1-Δ19-76* suppressed this defect ( [Figure 7A](#F7){ref-type="fig"}). Again using time-lapse imaging, we examined Sla1, Sla2, and Abp1 for fluorescence lifetimes and movement ( [Figure 7, C, D, and G](#F7){ref-type="fig"}). In *myo3Δ myo5Δ* cells the lifetimes of Sla2 patches were extremely delayed compared with wild type, and only 8% of patches internalized, consistent with previous work ( [@B71]). However, these phenotypes were rescued by combination with the *clc1-Δ19-76* allele. Sla2-GFP lifetimes decreased from 226 ± 102 to 56 ± 36 s (p ≤ 0.0001, *myo3Δ myo5Δ* vs. *myo3Δ myo5Δ clc1-Δ19-76,* respectively; [Figure 7, D and G](#F7){ref-type="fig"}), and the percentage of internalizing patches rose to 58% when *clc1-Δ19-76* was present in the myosin mutant. We also saw a mild effect of *clc1-Δ19-76* in *myo3Δ* (unpublished data) or *myo5Δ* alone ( [Figure 7, A and C--G](#F7){ref-type="fig"}), although generally the single myosin mutants were only slightly defective on their own, which explains why they did not appear in the SGA screen.

![Endocytic defects caused by elimination of the type I myosins (*myo3Δ myo5Δ*) or WASp (*las17Δ*) are suppressed by *clc1-Δ19-76.* (A) Growth with *myo3Δ myo5Δ*: wild type (SL1462), *clc1-Δ19-76* (SL6044), *myo3Δ myo5Δ* (SL6561), *myo3Δ myo5Δ clc1-Δ19-76* (SL6576), *myo5Δ* (SL6580), and *myo5Δ clc1-Δ19-76* (SL6579) were fivefold serially diluted, plated on YEPD, and grown at 30 or 37°C for 60 h. (B) Growth of *las17Δ* (SL6602) and *las17Δ clc1-Δ19-76* (SL6603) as in A. (C) Representative kymographs of Sla1-GFP/Abp1-RFP patches in wild type (SL5311), *myo5Δ* (SL6579), *myo5Δ clc1-Δ19-76* (SL6554), *myo3Δ myo5Δ* (SL6562), and *myo3Δ myo5Δ clc1-Δ19-76* (SL6575). (D) Representative kymographs of Sla2-GFP/Abp1-RFP patches in wild type (SL5311), *myo5Δ* (SL6569), *myo5Δ clc1-Δ19-76* (SL6572), *myo5Δ myo3Δ* (SL6566), and *myo3Δ myo5Δ clc1-Δ19-76* (SL6568). (E) Representative kymographs of Sla1-GFP/Abp1-RFP patches in *las17Δ* (SL6596) and *las17Δ clc1-Δ19-76* (SL6597). (F) Representative kymographs of Sla2-GFP/Abp1-RFP patches in *las17Δ* (SL6598) and *las17Δ clc1-Δ19-76* (SL6600). (G) Fluorescence lifetimes of Sla2-GFP, Sla1-GFP, and Abp1-RFP in strains shown in C--F. Data are reported as average ± SD (n ≥ 50). †p ≤ 0.0009 vs. wild type; \*p ≤ 0.004 vs. wild type; \#p ≤ 0.0001 vs. *myo3Δ myo5Δ*; °p ≤ 0.0003 vs. *myo5Δ*; ‡*p* ≤ 0.0001 vs. *las17Δ.*](3699fig7){#F7}

Deletion of *LAS17* caused temperature-sensitive growth at 37°C, which was also suppressed by *clc1-Δ19-76* ( [Figure 7B](#F7){ref-type="fig"}). *las17Δ* greatly increased both Sla1-GFP (80 ± 38 s), as shown previously ( [@B71]), and Sla2-GFP (124 ± 62 s) lifetimes compared with wild type ( [Figure 7, E--G](#F7){ref-type="fig"}). When *las17Δ* was combined with *clc1-Δ19-76* the lifetime of Sla1 was restored to normal (33 ± 7 s, p ≤ 0.0001 vs. *las17Δ*), and there was significant improvement of the lifetime of Sla2 (78 ± 36 s, p ≤ 0.0001 vs. *las17Δ*; [Figure 7, E--G](#F7){ref-type="fig"}). Of interest, *clc1-Δ19-76* also suppressed the extended lifetime of Abp1-RFP in *las17Δ* or *myo3Δ myo5Δ* ( [Figure 7, C--G](#F7){ref-type="fig"}), which was not observed for *vrp1Δ* and *rvs167Δ* ( [Figures 3C](#F3){ref-type="fig"} and [4C](#F4){ref-type="fig"}). Overall these results show that *clc1-Δ19-76* also suppresses endocytic defects caused by loss of the major NPFs.

DISCUSSION
==========

In this study we performed SGA with yeast containing a deletion of the Sla2-binding region of CLC in order to elucidate the functional significance of this interaction in vivo. This unbiased approach identified a large number of negative genetic interactions with *clc1-Δ19-76,* including many with components involved in clathrin-mediated transport and TGN/endosomal trafficking. We focused on three endocytic factors, Vrp1, Rvs167, and Rvs161, whose mutations were suppressed by *clc1-Δ19-76,* as positive genetic interactions were likely to be specific to the *clc1-Δ19-76* allele and provide information on the regulatory role of the CLC--Sla2 interaction.

On the basis of our results, we propose the model shown in [Figure 8](#F8){ref-type="fig"}, where CLC--Sla2 interaction prevents Sla2 binding to F-actin. This CLC inhibition would thereby restrict the number of attachments between Sla2 and actin, possibly to an area near the neck or edge of the clathrin coat ( [Figure 8A](#F8){ref-type="fig"}). Consistent with this, immuno--electron microscopy (immuno-EM) of unroofed cells showed Hip1R associated with actin filaments primarily at the edge of clathrin lattices and pits ( [@B18]). In yeast Sla2--actin attachments at the edge of the pit may provide directionality to the force produced by actin assembly or even assist in vesicle scission. CLC is likely to achieve this regulation by causing conformational changes of Sla2 that regulate THATCH accessibility to actin. Self-interaction of the THATCH and coiled-coil regions of Sla2 were first suggested by two-hybrid analysis ( [@B85]). Electron microscopy of purified Hip1R or Hip1 showed the existence of both compact and extended profiles of the proteins ( [@B18]; [@B80]), but the more compact structures are more prevalent in the presence of a 22--amino acid clathrin LCa N-terminal peptide containing the CLC-Hip1/R binding site ( [@B80]). Moreover, in surface plasmon resonance analysis the CLC NT peptide decreased the affinity of Hip1 or Hip1R binding to F-actin, suggesting that CLC binding in vitro negatively regulates Hip1/R attachments to actin by promoting Hip1/R self-interaction ( [@B80]).

![Model for CLC regulation of Sla2 binding to F-actin at endocytic patches. (A--C) Model of endocytic patches in wild type (A), *rvs167Δ* (B), and *vrp1Δ* (C). (D, E) Models for how preventing CLC regulation of the Sla2--actin interaction helps to overcome amphiphysin (D) and verprolin (E) mutants by increasing attachments to F-actin. Suppression of *myo3/5Δ* and *las17Δ* is similar to that of *vrp1Δ.*](3699fig8){#F8}

Our work provides the first in vivo studies to support this regulatory model by showing that *clc1-Δ19-76,* a *clc1* mutant lacking its Sla2 interaction domain, can overcome several mutations leading to reduced late-stage actin assembly (*vrp1Δ,* *myo3Δ myo5Δ,* *las17Δ*) or failure to adequately narrow the neck of a vesicle (*rvs167Δ*/*rvs161Δ*). Recent studies suggested that CLC-NT prevents bending of the CHC knee, which impairs clathrin assembly ( [@B81]). Thus, deletion of the CLC-NT in our studies could be more favorable for formation of a curved lattice and promote membrane deformation. However, *clc1-Δ19-76* suppression of *vrp1Δ* and *rvs167Δ* depended on the actin-binding THATCH region of Sla2, which is more consistent with a mechanism of suppression involving Sla2 interaction with the actin cytoskeleton.

Immuno-EM analysis showed that the N-BAR proteins Rvs161 and Rvs167 are situated along the tubular invagination above the clathrin coat. This is consistent with their association with the narrowing neck of the invaginating vesicle and function in constriction of the membrane, leading to vesicle scission ( [@B40]; [@B37]). New studies suggest that the amphiphysins may work in concert with the yeast dynamin Vps1, although the endocytic defects of *vps1* mutants are much less severe and went unnoticed for some time ( [@B54]; [@B67]; our unpublished data). Although actin assembly would be robust in the amphiphysin mutants, the lack of constriction on the neck would impair scission, which is observed as retraction events by live-cell imaging ( [@B40]; [@B67]; [@B90]; [Figure 8B](#F8){ref-type="fig"}). At the end of retraction, usually the coats and actin dissipate. We suggest that increased binding to actin by Sla2 allowed by the *clc1-Δ19-76* mutation might overcome this by stabilizing the coat and actin network ( [Figure 8D](#F8){ref-type="fig"}). This could drive the invaginations deeper into the cell, thus narrowing the neck of the invagination, or the new attachments could promote scission directly. Supporting this, in some cases we observed multiple retraction events and then internalization, as if the stabilization of the patch allowed added coat and actin assembly and new attempts at vesicle scission (D.R.B., unpublished observations).

The role of verprolin is to recruit and activate the type I myosins and is thus critical for the actin assembly burst that drives invagination ( [@B1]; [@B26]; [@B66]; [@B71]). In yeast lacking Vrp1 (or myosin I function), there is no obvious inward movement of the endocytic coat ( [Figure 8C](#F8){ref-type="fig"}), despite the fact that the actin marker Abp1 is recruited ( [@B71]). Residual actin assembly is likely provided by other endocytic NPFs, including Las17 (WASp); however, these may not be sufficient or properly positioned to drive invagination when the myosin function is impaired. We suggest that this defect is overcome by *clc1-Δ19-76* since it would increase the duration of Sla2 binding to actin, as well as affect the location and number of attachments ( [Figure 8E](#F8){ref-type="fig"}). In addition, this may stabilize the actin network to overcome the reduced NPF activity caused by *vrp1Δ*\'s effects on Myo3/5 activity.

Because *clc1-Δ19-76* could suppress *vrp1Δ,* one might predict that the *clc1-Δ19-76* allele could suppress other NPF mutations. Abp1 is a weak NPF, and *abp1Δ* has no phenotype on its own, so we did not expect to see suppression by the *clc1* mutation. However, our genetic screens found that *clc1-Δ19-76* exacerbated the growth defect of *pan1-4* (discussed later). We directly examined the three most potent NPF activities at the endocytic patch, Las17, and type I myosins ( [@B82]; [@B20]; [@B43]; [@B16]; [@B29]), which were not identified in the SGA screen. We found that *clc1-Δ19-76* also suppressed the growth and endocytic defects of l*as17Δ* and *myo3Δ myo5Δ.* Thus the model for verprolin ( [Figure 8](#F8){ref-type="fig"}) applies to these NPFs as well. Although *las17Δ* was not tested, three las17 *ts* alleles were analyzed by SGA, but their phenotypes may have been either too weak or too severe to observe suppression in a large-scale screen. Redundancy of the type-I myosins likely prevented their identification in the SGA.

We note that there was a difference in the suppression of *vrp1Δ* as compared with *las17Δ or myo3Δ myo5Δ,* in that *clc1-Δ19-76* suppressed the slowed Abp1 lifetime of these NPF mutations but not that of *vrp1Δ.* The reason for this distinction is not clear. Because Vrp1 binds both Las17 and the myosins, we suggest that Vrp1 also regulates the activity of the WASp. Thus in *vrp1Δ* the stimulatory activity of each of the major NPFs might be impaired, extending the time needed to produce a competent F-actin network for internalization. In *las17Δ or myo3Δ myo5Δ,* at least one of the major NPFs would still be active.

*PAN1* is one of the few essential endocytic genes. It encodes a scaffolding coat factor that binds several other endocytic coat proteins. Pan1 arrives at endocytic patches ∼20--30 s before the actin phase and has weak NPF activity ( [@B39]; [@B71]; [@B33]). In addition, the central domain of Sla2 (including the coiled-coil region) binds Pan1 and negatively regulates Pan1 NPF activity in vitro. Because the *pan1-4* product lacks its NPF activation domain ( [@B48]), we initially surmised that the genetic interaction with *clc1-Δ19-76* might be due to Pan1\'s importance in priming actin assembly at the coat to initiate curvature. We tested this using *pan1-20,* which results in a truncation downstream of the NPF actin activation region but deletes the C-terminal proline-rich domain (PRD; [@B3]). This mutant also caused synthetic lethality with *clc1-Δ19-76,* consistent with the *pan1-4* SGA results. These data suggest that the CLC-NT shares redundancy with functions of the Pan1-PRD, which may include the role of PRDs in binding to SH3-domain proteins ( [@B3]). However, we also cannot rule out that one role of CLC-NT binding to Sla2 may be to release Sla2\'s reported negative regulation of Pan1 NPF activity ( [@B75]). The loss of CLC--Sla2 interaction might lead to prolonged Sla2 inhibition, which in the context of an impaired Pan1 could be severely detrimental. Further studies are needed to uncover the basis for this synthetic lethality.

In mammals, Hip1R binds F-actin barbed ends in association with cortactin, which inhibits actin filament depolymerization in vitro ( [@B42]). This was suggested to channel new actin assembly and to stabilize F-actin. Despite a lack of a cortactin homologue in yeast, suppression by *clc1-Δ19-76* may involve a broader distribution of anchoring surrounding the invagination and increased stability of the network by barbed end binding. We note that capping protein also binds to barbed ends and terminates filament elongation, but Sla2 is unique in that its ANTH region would also serve to tether the membrane to actin. In fact, complete absence of Sla2 leads to impaired invagination and unproductive actin comet tails emanating from the cell surface ( [@B39]). Thus, localized Sla2 contact with F-actin performs a unique function in directing elongation of the membrane protrusions and/or scission.

The invaginating sites in yeast have an extended tubular morphology with a clathrin coat at the tip and actin assembled surrounding the tubule ( [@B37]). This architecture of such tubular assemblies with associated actin and clathrin has also been observed in mammalian cells. For example, internalizing vesicular stomatitis virus was found in deep invagination profiles with a clathrin cap at its base and an extensive actin network along the membrane surrounding the virus extending up to the cell surface, suggesting that actin is required for clathrin-mediated endocytosis of large particles ( [@B14]). In addition, long actin-dependent tubules with clathrin pits at the tip are generated in dynamin 1 and 2 double-knockout cells ( [@B21]). These endocytic structures have been recapitulated in vitro from plasma membrane sheets incubated in the presence of cytosol and GTPγS, which blocks scission ( [@B84]). Although the manner in which these structures are formed is unknown, they share remarkable similarities with yeast tubular invaginations, suggesting a role for Hip1 and Hip1R in their formation.

In summary, we believe that our results support the idea that a major role of CLC is to control endocytic progression by pruning the Sla2--actin attachments in the endocytic coat so that anchoring is restricted, possibly to the edge or neck of the invaginating vesicle. Releasing attachments in the coat could contribute to development of the endocytic vesicle and may be needed to promote directional membrane internalization. Restricting attachments to near the neck might also promote vesicle scission.

MATERIALS AND METHODS
=====================

Yeast strains and growth assays
-------------------------------

*Saccharomyces cerevisiae* strains used in this study are listed in Supplemental Table S1A. Standard methods and media were used for genetic manipulations, growth, and transformation of yeast ( [@B31]). To perform growth-plating assays, overnight log-phase liquid cultures were diluted to a starting concentration of 5 × 10^6^ cells/ml and then fivefold serially diluted in 96-well plates. Diluted cells were pinned with a multiprong frog onto yeast extract/peptone/dextrose (YEPD) plates and grown at indicated temperatures for 48--60 h.

Generation of the integrated clathrin light-chain allele (*clc1-Δ19-76:NatMX6*) was done as follows. First a HisMX6 PCR fragment, flanked by *Nco*1 sites with *CLC1* ends to excise codons 19--76, was cotransformed into yeast with pRS424 containing *CLC1.* Recombinant plasmids were shuttled into bacteria from Trp+ His+ colonies, cut with *Nco*1, and ligated to excise the *HisMX6,* yielding pTM45 with the *clc1-Δ19-76* allele. Note that the religation changed codon 19 from GAC (Asp) to GAA (Glu) and inserted two codons representing the *Nco*I site: CCA (Pro) and TGG (Trp). Next the NatMX6 marker was PCR amplified from a pFA6a-NatMX6 template and integrated via homologous recombination downstream of the *clc1-Δ19-76* coding sequence in pTM45. The resultant plasmid (pDRB1) was used as a template for two PCR amplifications. The first contained the 5′ flanking *CLC1* DNA, the mutant allele, and 500 nucleotides of the NatMX6 marker. The second contained the full NatMX6 marker followed by 3′ sequence flanking *CLC1.* These products were cotransformed into the SGA tester strain y7092 ( [@B74]), as well as our laboratory wild-type strain (SL1462) for split marker recombination ( [@B10]), and screened for simultaneous recombination at the *CLC1* locus, generating SL5677 and SL6044, respectively. The integrated mutant alleles were recovered by PCR and confirmed by DNA sequencing.

The integrated *SLA2-GFP:TRP1* was generated by homologous recombination as previously described ( [@B78]; [@B51]), using pFA6a-*TRP1* as a template. Similarly, *SLA2-HA:HisMX6* and *SLA2-ΔTHATCH-HA:HisMX6* were generated using pFA6a-3HA-HisMX6 as the template. The coding sequence for the HA tag in *SLA2-ΔTHATCH-HA:HisMX6* was integrated after *SLA2* codon 716. Strains for endocytic factor lifetimes and phenotypic analyses were created by standard genetic crosses. To avoid problems of polyploidy found in clathrin-null strains, haploid *clc1Δ:HIS3* spores that segregated from tetrads with pKH2 (*CLC1,* 2 μ, *URA3*) ( [@B35]) were used in crosses. Diploids were selected, grown on 5-fluoroorotic acid to drop the *CLC1* plasmid, and then sporulated and dissected.

SGA screens
-----------

SGA screens were conducted as described ( [@B72]). In one screen the *clc1-Δ19-76:NatMX6* query strain (SL5677) was crossed to a miniarray consisting of 177 strains with *ts* mutations in genes annotated with roles in actin, endocytosis, and vesicle trafficking ([www.yeastgenome.org](http://www.yeastgenome.org); Supplemental Table S1B). Construction of the *ts* mutant strains and methodology for screening them have been described ( [@B48]). The second screen was performed against an array of 3885 nonessential null mutants. Genetic interactions from the SGA screens were processed and identified as previously described ( [@B73]). The results from the knockout screen were normalized and the interactions measured as deviations from the null mutant alone. These relative fitness measurements were used to assign genetic interaction scores ε as described in [@B13]. Results here are reported as synthetic rescue if they had ε \> 0.16 and p \< 0.05. Results are reported as synthetic growth defects if they had ε \< −0.12 and p \< 0.05.

Assignment of screen results to biological process (Supplemental Table S2) was performed based on Gene Ontology assignments using Slim-Go enrichment at the *Saccharomyces* Genome Database ([www.yeastgenome.org](http://www.yeastgenome.org)) and then manually refined. To perform network analysis, each screen hit was used as a node, and additional node/edge attributes (from the *Saccharomyces* Genome Database) were layered onto the data set using Cytoscape ( [@B41]). Known physical interactions were used to identify protein complexes ( [Figures 1, D--G](#F1){ref-type="fig"}) using the MCODE plug-in for Cytoscape ( [@B2]).

Microscopy and image analysis
-----------------------------

Live-cell imaging of endocytosis was carried out essentially as described in [@B7]. Cells were grown to log phase at 25°C in synthetic medium, concentrated, immobilized on polylysine-coated coverslips, mounted on slides in 1.6% agarose, and then imaged at 25°C. All fluorescence lifetimes were calculated from movies acquired on an Olympus (Center Valley, PA) BX71 inverted microscope equipped with differential interference contrast (DIC) optics, an UPlan Apo 150× total internal reflection fluorescence objective (numerical aperture \[NA\], 1.45), Hamamatsu (Hamamatsu, Japan) ImagEM C910013 512 × 512 bit EM charge-coupled device camera, and a Sutter Instrument (Novato, CA) Lambda DG4 rapid wavelength switcher with a 300-W xenon lamp. Images were captured using SlideBook 4.2 for PC platform (Intelligent Imaging Innovations, Denver, CO). Following capture, all movies were photobleach corrected in SlideBook using the exponential correction function. Average patch lifetimes and standard deviations were determined from 30--40 patches for each strain. Student\'s *t* test was used to calculate p values. All kymographs, projection images, and example micrographs were generated in SlideBook and then exported to Adobe Photoshop (San Jose, CA) for figure assembly.

Single-particle tracks were generated from movies exported from SlideBook into ImageJ (National Institutes of Health, Bethesda, MD) using the plug-in ParticleTracker ( [@B63]). Particle trajectories that aligned 90 deg from the cell cortex were converted from pixel to metric distances and graphed using SigmaPlot.

All other microscopy was carried out on an Olympus fluorescence BX61 upright microscope equipped with Nomarski DIC optics, a UPlan S Apo 100× objective (NA 1.4), a CoolSnap HQ camera (Roper Scientific Germany, Ottobrunn, Germany), Sutter Instrument Lambda 10-2 excitation and emission filter wheels, and a 175-W xenon remote source with liquid light guide. Image capture was automated using SlideBook 4.01 for the Mac.

Analysis of actin polarization in phalloidin stained cells was done as follows. Cells were grown in YEPD to a concentration of 5 × 10^6^ cells/ml at 30°C. Formaldehyde was added directly to growth medium to a final concentration of 4%, and cultures were continued for 10 min. Cells were collected and resuspended in phosphate-buffered saline (PBS; 140 mM NaCl, 2.7 mM KCl, 10 mM Na~2~HPO~4~, 1.8 mM KH~2~PO~4~) containing 4% formaldehyde and incubated at room temperature for an additional 1 h. After two washes in PBS, cells were stained overnight at 4°C with 6.6 μM Alexa 568--phalloidin (Molecular Probes, Invitrogen, Carlsbad, CA). Cells were washed five times in PBS and immobilized on polylysine-coated coverslips for imaging. A series of optical Z-sections (0.2 μm) ware captured and then deconvolved by the nearest-neighbor algorithm and projected into a single plane using SlideBook. Polarization of actin was quantified on cells with small or medium-size buds as described by [@B6]). Total fluorescence measurements were made for the whole cell and the mother cell in SlideBook. Cells with more than 50% of the total fluorescence in the mother cell were scored as nonpolarized (n = 50).

Lucifer yellow (Molecular Probes) uptake was performed at 30°C for 1 h as described in [@B15]).

Biochemical methods
-------------------

Bacterial expression plasmids for GST-Sla2 (pTMN5), GST-Sla2-(292-968), and 6xHis-Clc1 (pTMN3) are described in [@B57]). GST-Crn1 was expressed in bacteria from pGAT2-CRN(1--651) ( [@B30]). The vector for expression of GST-Sla2-(717-968) (pDRB7) was generated by ligation of a *SLA2* PCR fragment encoding amino acids 717--968 (THATCH domain) with *Bam*H1/*Sal*1 ends into pGEX-4t.

GST fusions were expressed in Rosetta *Escherichia coli* (Agilent Technologies, Santa Clara, CA). Cultures were grown to log phase at 37°C, then induced with 0.5 mM isopropyl-β-[d]{.smallcaps}-thiogalactoside for 6 h at 25°C. After pelleting, cells were resuspended in lysis buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na~2~HPO~4~, 1.8 mM KH~2~PO~4~, pH 7.3) containing 0.5% Triton X-100 (v/v), 1 mM dithiothreitol (DTT), a protease inhibitor cocktail ( [@B68]), and lysozyme (0.5 mg/ml) and incubated on ice for 15 min. Cells were lysed by sonication, and the lysate was cleared by centrifugation at 16,000 × *g* for 20 min. GST fusions were absorbed from the cleared supernatant onto glutathione--agarose beads (GE Healthcare, Piscataway, NJ) for 1.5 h on a rocker at 4°C. Beads were loaded into a poly-prep chromatography column (0.8 × 4 cm; Bio-Rad, Hercules, CA) and washed in 10 column volumes of lysis buffer, and then GST fusions were eluted in 50 mM Tris-HCl, pH 8.0, 10 mM reduced glutathione, and 1 mM DTT. Peak fractions were exchanged into actin assembly buffer (see later discussion), concentrated in a Centricon-10 size exclusion filter (Millipore, Billerica, MA), brought up to 10% glycerol, snap frozen, and stored at −80°C. The 6xHis-Clc1 (pTMN3) was expressed and purified from BL-21 *E. coli* (DE3) as described in [@B57]).

Actin cosedimentation assays were performed as described by [@B27]). Prior to use, all protein samples proteins were precleared by centrifugation at 100,000 × *g* in a Beckman Airfuge equipped with an A-100 rotor. Nonmuscle actin (Cytoskeleton, Denver, CO) was assembled for 1 h at room temperature in actin assembly buffer (4.5 mM Tris-HCl, 20 μM CaCl~2~, 50 mM KCl, 2 mM MgCl~2~, 1 mM ATP, pH 8.0). Assembled F-actin was added at a final concentration of 10 μM to either input proteins alone or input proteins preincubated for 1 h with a fivefold molar excess of 6xHis-Clc1. Input proteins were tested at the following concentrations: 3 μM GST-Sla2-292-958, 3 μM GST-Sla2-717-968, 1 μM GST-Sla2, and 1 μM GST-Crn1. Binding reactions were performed at 25°C for 1 h (typically in 50 μl ) in actin assembly buffer, and then actin and actin-associated proteins were pelleted by centrifugation in the Airfuge at 100,000 × *g* for 1 h at room temperature. The supernatant was removed and the pellet was resuspended in water. The supernatant and pellet were brought to equal volumes in SDS--PAGE loading buffer, boiled for 3 min, and separated by SDS--PAGE on 8--20% gradient polyacrylamide gels (Invitrogen). Gels were stained with Coomassie brilliant blue, and high-resolution images were captured for densitometry analysis using ImageJ. Trapping of soluble proteins was accounted for by sedimentation of bovine serum albumin (2 μM) in the presence of 10 μM F-actin.

For immunoblots of clathrin LC and HC, cultures were grown to log phase (5 × 10^6^ cells/ml) at 30°C, and 10 ml were concentrated and subjected to glass bead lysis in 250 μl of 0.1 M Tris, pH 7.5, containing 1 mM phenylmethylsulfonyl fluoride and a protease inhibitor cocktail ( [@B68]). Lysates were centrifuged for 20 min at 10,000 × *g,* and equivalent volumes of the supernatants were analyzed by SDS--PAGE and immunoblotted using anti-Chc1 mouse monoclonal antibodies ( [@B46]), anti-Clc1 rabbit polyclonal antiserum (a gift from Greg Payne), or anti-PGK1 mouse monoclonal antibodies (Molecular Probes) as a loading control. Antibody decoration was detected by an Odyssey Infrared Imaging System (LiCor, Lincoln, NE) using IRDye700- or IRDye800-conjugated secondary antiserum (LiCor).
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CHC

:   clathrin heavy chain

CLC

:   clathrin light chain

GFP

:   green fluorescent protein

NT

:   N-terminus

RFP

:   red fluorescent protein

SGA

:   synthetic genetic array

THATCH

:   talin-Hip1/R/Sla2 actin-tethering C-terminal homology

*ts*

:   temperature sensitive
